MedTrace Logo

Safety And Efficacy Study Of Ziprasidone In Pediatric Psychotic Illness

NCT00199940 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2008-03-12

No results posted yet for this study

Summary

The purpose of this research is to determine if Ziprasidone is safe and effective for use in children and adolescents with a psychotic illness, and to determine of Ziprasidone treatment leads to weight changes in children.

Conditions

  • Schizophrenia
  • Affective Disorders
  • Psychotic Disorder
  • Psychotic Mood Disorder

Interventions

DRUG

Ziprasidone

Sponsors & Collaborators

  • Medical College of Wisconsin

    lead OTHER

Principal Investigators

  • Russell E Scheffer, MD · Medical College of Wisconsin; Children's Hospital of Wisconsin

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
7 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Completion
2007-04-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00199940 on ClinicalTrials.gov